Ontology highlight
ABSTRACT: Background
Clinical indications for ibrutinib reimbursement in Australia should consider the inclusion of patients with chronic lymphocytic leukemia (CLL) harboring prognostically unfavorable TP53/IGHV genomic aberrations. This study assessed the cost effectiveness of five first-line treatment strategies in CLL for young (aged ≤ 65 years), fit patients without significant comorbidities: (1) no testing (fludarabine, cyclophosphamide and rituximab [FCR] for all), (2) test for del(17p) only, (3) test for TP53 gene mutation status, (4) test for TP53 and IGHV gene mutation status and (5) no testing (ibrutinib for all).Method
A decision analytic model (decision tree and partitioned survival model) was developed from the Australian healthcare system perspective with a lifetime hor
SUBMITTER: Vu M
PROVIDER: S-EPMC10761538 | biostudies-literature | 2024 Jan
REPOSITORIES: biostudies-literature